The recent Association for Molecular Pathology v. Myriad Geneticspatent dispute involving two genes for breast and ovarian cancer, BRCA 1 and BRCA 2, has been widely followed by the media over the last several years. According to some the case highlights a potentially devastating future where humans have no control over their very own genetic code. Even worse, they say, patenting sequences of human DNA limits academic research and delays inevitable benefits to society. While there is certainly cause for concern I believe the recent attacks on Myriad Genetics, Inc. (NASDAQ: MYGN) have been a bit overdone.
View the original article here: Myriad Genetics patent dispute: Genes are patentable, and that’s OK, says author